^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    EGFR (Epidermal growth factor receptor)

    i
    Other names: EGFR, ERBB, ERBB1, Epidermal growth factor receptor
    1d
    LUNG-MAP Sub-Study: Targeted Treatment for RET Fusion-Positive Advanced Non-Small Cell Lung Cancer (A LUNG-MAP Treatment Trial) (clinicaltrials.gov)
    P2, N=124, Active, not recruiting, SWOG Cancer Research Network | Trial completion date: Mar 2026 --> Dec 2026 | Trial primary completion date: Mar 2026 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    BRAF V600E • KRAS mutation • EGFR mutation • BRAF V600 • EGFR T790M • RET fusion • MET exon 14 mutation • ALK fusion • ROS1 fusion • MET mutation • RET positive
    |
    FoundationOne® CDx
    |
    Retevmo (selpercatinib)
    1d
    LONESTAR: Nivolumab and Ipilimumab With or Without Local Consolidation Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P3, N=339, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Mar 2026 --> Mar 2027 | Trial primary completion date: Mar 2026 --> Mar 2027
    Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab)
    3d
    Boosting osimertinib Blood Brain Barrier penetration in patients with epidermal growth factor receptor mutated non-small cell lung cancer (OSIBBBOOST) (2025-523033-26-00)
    P1/2, N=14, Not yet recruiting, Academisch Ziekenhuis Maastricht
    New P1/2 trial
    |
    EGFR (Epidermal growth factor receptor) • CD4 (CD4 Molecule)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion
    |
    Tagrisso (osimertinib)
    4d
    OSIBBBOOST: Boosting Osimertinib Blood Brain Barrier Penetration (clinicaltrials.gov)
    P2, N=7, Not yet recruiting, Maastricht University Medical Center
    New P2 trial
    |
    EGFR (Epidermal growth factor receptor) • CD4 (CD4 Molecule)
    |
    EGFR mutation
    |
    Tagrisso (osimertinib)
    4d
    KANNON-5: Andamertinib With or Without Platinum-doublet Chemotherapy Versus Platinum-doublet Chemotherapy in Patients With NSCLC Harboring Atypical EGFR Mutations (clinicaltrials.gov)
    P2, N=40, Recruiting, Avistone Biotechnology Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation
    |
    andamertinib (PLB1004)
    4d
    CPO301-US-101: A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=132, Recruiting, Conjupro Biotherapeutics, Inc. | Trial completion date: Dec 2025 --> Aug 2027 | Trial primary completion date: Jun 2025 --> May 2027
    Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase)
    |
    EGFR mutation • KRAS wild-type • RAS wild-type
    |
    SYS6010
    4d
    Reducing the Incidence of Symptomatic Brain Metastases With MRI Surveillance (clinicaltrials.gov)
    P2, N=60, Recruiting, Wake Forest University Health Sciences | Trial completion date: Jun 2027 --> Apr 2028 | Trial primary completion date: Jun 2027 --> Apr 2028
    Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor)
    4d
    Non-invasive host transcriptome and HPV oncogene expression map the molecular landscape of HPV-driven cervical lesions. (PubMed, PLoS One)
    By integrating transcriptomics profiling with current clinical testing, clinicians can distinguish transient infections from high-risks lesions likely to progress. This combined approach addresses the critical limitations of morphology and DNA-based methods, enabling more precise therapeutic interventions and reducing unnecessary overtreatment, and the risk of undertreatment or dismissal of high-risk cases.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • CCND1 (Cyclin D1) • PLK1 (Polo Like Kinase 1) • CDK1 (Cyclin-dependent kinase 1) • DEFA1 (Defensin Alpha 1)
    4d
    Mining whole-brain information with deep learning to predict EGFR mutation and subtypes in brain-metastatic NSCLC: A multicenter study. (PubMed, Med Phys)
    The developed ESR-Net demonstrates promising potential for early detection of EGFR mutations and subtypes with multicenter data, which may promote optimal treatment management for patients with brain metastatic NSCLC.
    Clinical • Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L858R
    4d
    UNLOCK ASP3082: Study Investigating ASP3082 in Patients With Metastatic/Locally Advanced Non-small-cell Lung Cancer (NSCLC) and Pancreatic Ductal Adenocarcinoma (PDAC), With Biomarker Analysis to Characterize Response/Resistance (clinicaltrials.gov)
    P2, N=60, Not yet recruiting, Gustave Roussy, Cancer Campus, Grand Paris
    New P2 trial
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    KRAS mutation • EGFR mutation • BRAF mutation • KRAS G12D • RET fusion • RET mutation • ROS1 fusion • MET mutation • KRAS G12 • NTRK fusion
    |
    setidegrasib (ASP3082)
    4d
    19-C-0017: Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients (clinicaltrials.gov)
    P1/2, N=5, Completed, National Cancer Institute (NCI) | N=70 --> 5 | Recruiting --> Completed
    Trial completion • Enrollment change • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase) • NRAS (Neuroblastoma RAS viral oncogene homolog) • HRAS (Harvey rat sarcoma viral oncogene homolog)
    |
    PD-L1 expression • KRAS mutation • NRAS mutation • KRAS G12D • EGFR expression • HRAS mutation • KRAS G12 • NRAS G12
    |
    cyclophosphamide • fludarabine IV • Proleukin (aldesleukin) • anti-KRAS G12D mTCR PBL
    4d
    Furmonertinib Plus Radiotherapy for EGFR+ NSCLC With Pleural Effusion (clinicaltrials.gov)
    P2, N=63, Not yet recruiting, Jiangmen Central Hospital
    New P2 trial
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR positive
    |
    Ivesa (firmonertinib)